Opexa Therapeutics:

Precision Immunotherapy™

Tcelna®:

Personalized T-cell immunotherapy

Abili-T:

A phase II clinical study for patients with Secondary Progressive Multiple Sclerosis

NASDAQ: OPXA: $ 1.04
CHANGE: +0.00CHANGE: +0% Volume: 184,400 October 22, 2014

Opexa Investor Update

October 9, 2014 Opexa Therapeutics Investor Update
08:00 AM EDT
The New York Hilton Midtown
Madison Room
View the live Webcast

Corporate Overview

Opexa Therapeutics, Inc. (NASDAQ:OPXA) is a publically traded biotechnology company developing personalized immunotherapies with the potential to treat major illnesses, including multiple sclerosis (MS) as well as other autoimmune diseases, such as neuromyelitis optica (NMO). These therapies are based on Opexa’s proprietary T-cell technology. The Company’s leading therapy candidate, Tcelna®, is a personalized T-cell immunotherapy that is in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive MS. 

Opexa’s mission is to lead the field of Precision Immunotherapy™ by aligning the interests of patients, employees and shareholders.

MORE INFORMATION

Tcelna® (imilecleucel-T) is an autologous T-cell immunotherapy being developed for the treatment of Multiple Sclerosis (MS), and is specifically tailored to each patient's immune response profile to myelin.
OPX-212 is an autologous T-cell immunotherapy being developed for the treatment of Neuromyelitis Optica (NMO). OPX-212 is specifically tailored to each patient’s immune response to aquaporin-4.
MORE MORE

DateScript